We have previously characterized 15-hydroxyprostaglandin dehydrogenase (15-PGDH), the enzyme responsible for the rate-limiting step of PGE2 degradation, as a potential therapeutic target to augment tissue regeneration in models of bone marrow transplant and IBD [44]; these findings have further established the positive role of PGE2 and the negative role of 15-PGDH in organ self-renewal. Here, HPGD is linked to inflammatory bowel disease.